search

AstraZeneca Says Drug Cocktail Effective Against COVID-19 in Late-Stage Study

European drugmaker AstraZeneca this week said a late-stage study showed its antibody drug cocktail is effective at keeping COVID-19 patients out of hospitals. The phase 3 trial preliminary results showed the drug, a long acting antibody (LAAB) combination, cut the risk of developing severe COVID-19 or dying by 50 percent compared to a placebo in people who did not require hospitalization and had been showing symptoms for a week or less. The drug, AZD7442, was even more effective when given within five days of symptom onset, according to AstraZeneca. “These positive results show that a convenient intramuscular dose of AZD7442 could play an important role in helping combat this devastating pandemic,” Mene Pangalos, executive vice president of biopharmaceuticals research and development at AstraZeneca, said in a statement. Early trial results were based on an analysis of 822 participants. The trial included 903 participants, about half of whom were given a placebo. …

Related Post

This website uses cookies.